ArticleVaccine2009
Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives.
Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Amyloid-β targeting immunisation in aged non-human primate (Microcebus murinus).Brain, behavior, and immunity · 2023Article
- A Review of the Current Mammalian Models of Alzheimer's Disease and Challenges That Need to Be Overcome.International journal of molecular sciences · 2021Review
- CAV-2 Vector Development and Gene Transfer in the Central and Peripheral Nervous Systems.Frontiers in molecular neuroscience · 2019Review
- Article
- Alzheimer's disease: experimental models and reality.Acta neuropathologica · 2017Review
- Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition.Neurobiology of aging · 2015Article
- Lessons from the analysis of nonhuman primates for understanding human aging and neurodegenerative diseases.Frontiers in neuroscience · 2015Review
- Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds.Neurobiology of aging · 2013Article
- Article
- Age-associated cerebral atrophy in mouse lemur primates.Neurobiology of aging · 2011Article
- Article
- Amyloid-beta immunotherapy for Alzheimer's disease.CNS & neurological disorders drug targets · 2010Review
- Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.Alzheimer's research & therapy · 2010Article
- AD vaccines: conclusions and future directions.CNS & neurological disorders drug targets · 2009Review
- Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.CNS & neurological disorders drug targets · 2009Review
- Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.Journal of Alzheimer's disease : JAD · 2009Article
- Vaccination as a therapeutic approach to Alzheimer's disease.The Mount Sinai journal of medicine, New YorkReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
We have been developing Abeta derivative vaccines with the objective to improve the safety of Abeta targeting immunotherapy. Our Abeta homologs are designed to have less direct toxicity and to produce a modified immune response compared to Abeta. In extensive mouse studies, all our vaccines have improved cognition in transgenic mice while eliciting different immune responses and reducing brain amyloid burden to a variable degree. While we are continuing to characterize these vaccines in mice, in preparation for studies in old primates and for human trials we assessed their effect in young lemur primates (n=25) that with age develop Abeta plaques and tau aggregates as seen in Alzheimer's disease. In the primates, all the peptides administered with alum adjuvant elicited a moderate to robust anti-Abeta IgM response. Abeta1-42, K6Abeta1-30 and K6Abeta1-30[E(18)E(19)] resulted in a high anti-Abeta IgG response, whereas Abeta1-30[E(18)E(19)] produced a weaker more variable IgG titer. Notably, 22 weeks after the 3rd immunization, IgM and IgG levels in derivative-vaccinated primates were similar to preimmune values whereas Abeta1-42 treated primates maintained a moderate IgG titer. The increase in antibodies that recognized Abeta1-40 often correlated with increase in Abeta1-40 in plasma, which suggests that the antibodies were binding to Abeta in vivo. Interestingly, significant transient weight gain was observed (K6Abeta1-30-, Abeta1-30[E(18)E(19)]- and Abeta1-42-treated) or a trend in the same direction (K6Abeta1-30[E(18)E(19)]-treated, adjuvant controls) following the injections. Based on these findings, we have chosen K6Abeta1-30 for immunizations in old primates as the antibody response to this vaccine was less variable compared to other Abeta derivatives. Our present findings indicate that most of our Abeta derivatives elicit a substantial antibody response in primates, and importantly this effect is reversible which enhances the safety profile of our approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.